The iconic pottery maker reports encouraging sales growth and a renewed focus on its craft heritage, aiming to return to profitability next year after a period of job cuts and industry-wide challenges.
Amid broader market uncertainty, companies with high insider ownership and robust earnings forecasts can signal aligned interests and resilience. We examine three such UK-listed firms, from a gold miner to a convenience food giant, where those running the show have significant personal stakes.
The Singapore-listed food company has turned profitable after years of losses, with a 12% return on capital employed and a significant expansion in its capital base—key indicators watched by investors seeking compounding growth stocks.
Snapchat has disabled hundreds of thousands of accounts belonging to users under 16 in Australia under new social media laws, but warns the legislation contains 'significant gaps' that may allow some minors to bypass protections.
In Thailand's crucial northeast, a profound political realignment is underway. Farmers, disillusioned by unmet promises and economic hardship, are abandoning decades of party loyalty to back individual candidates, testing the foundations of the Shinawatra family's political machine ahead of pivotal elections.
As Thailand heads to the polls, three major parties offer starkly different visions for the nation's path forward, from populist subsidies to structural reforms, setting the stage for a pivotal political contest.
As the pet care market expands, investors weigh the focused approach of Chewy against Walmart's diversified scale. While Chewy offers pure exposure, Walmart's broader ecosystem and advertising growth present a compelling alternative.
Kuya Silver reports a record quarterly production haul from its Bethania silver mine alongside accelerated underground development, drawing investor focus. However, a premium valuation against a backdrop of ongoing losses presents a complex picture for the junior miner.
Lucky Strike Entertainment's stock has tumbled nearly 24% over the past year, raising critical questions about its true worth. We analyze whether the current price reflects underlying value or signals an overextended valuation.
Shares of insulin pump maker Tandem Diabetes Care have plummeted over 80% in five years, trading near $20. A deep dive into valuation metrics suggests the stock may now be modestly undervalued, but significant risks and competitive pressures remain.
After a recent pullback, Landstar System's (LSTR) shares present a complex valuation picture. While short-term momentum has improved, the stock trades at a significant premium to industry P/E ratios, raising questions about its growth prospects amid a mixed freight demand environment.
Travere Therapeutics faces a securities fraud investigation by Robbins Geller Rudman & Dowd LLP, raising questions about the accuracy of its past disclosures. The probe casts a shadow over the company's critical transition, as it banks on its kidney drug FILSPARI to drive growth amid mounting legal and commercial pressures.
Shares of Advantest Corp. have surged nearly 200% in the past year, riding the AI and advanced chipmaking wave. As the stock trades near record highs, investors are grappling with a critical question: has the rally run too far, too fast?
After a staggering 75% surge over the past year, Tapestry's stock is under the microscope. While a discounted cash flow model suggests the shares are roughly fairly valued, its sky-high P/E ratio tells a more cautionary tale, raising questions about whether the market's optimism has gotten ahead of itself.
Tripadvisor and Best Western's new AI-driven travel platform for the 2026 FIFA World Cup showcases the company's potential in high-stakes tourism. Yet, for investors, the real test remains translating innovation into sustained growth and market-beating returns.
Amid a patchy eurozone recovery, investors are scanning the market's fringes for potential. We spotlight three small-cap stocks from Norway and Sweden, each navigating unique challenges while showing flashes of promise for the discerning, risk-tolerant investor.
A sharp correction in Bitcoin prices has pushed MicroStrategy's massive holdings into significant paper losses, testing the resolve of the corporate sector's most vocal crypto advocate and raising questions about the sustainability of its accumulation strategy.
Sanofi's experimental oral drug venglustat demonstrated significant neurological benefits for patients with Type 3 Gaucher disease in a late-stage trial, but failed to meet its primary endpoint in a separate study for Fabry disease, casting uncertainty on its regulatory path.
Backed by regional sovereign wealth giants, Ruya Partners is launching a $400 million fund to address middle-market lending gaps in Saudi Arabia and the UAE, positioning itself as a key player in the Gulf's burgeoning private credit landscape.
After weeks of closure, the vital Rafah border crossing between Gaza and Egypt is set to resume limited operations, facilitating the movement of urgent humanitarian cases and some foreign nationals.
